您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > AC 261066
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
AC 261066
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
AC 261066图片
CAS NO:870773-76-5
包装:50mg
市场价:11897元

产品介绍
AC 261066 是一种有效的、可口服的、异构体选择性视黄酸β2 (RARbeta2) 受体激动剂，pEC50 为 8.0。
Cas No.870773-76-5
化学名4-(4-(2-butoxyethoxy)-5-methylthiazol-2-yl)-2-fluorobenzoic acid
Canonical SMILESFC1=CC(C2=NC(OCCOCCCC)=C(C)S2)=CC=C1C(O)=O
分子式C17H20FNO4S
分子量353.41
溶解度<35.34mg/ml in DMSO;<35.34mg/ml in ethanol
储存条件Store at RT
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

AC 261066 is an agonist of retinoic acid receptor subtype β isoform 2 (RARβ2) [1] [2]. It is also called UVI2062 [3]. AC 261066 exhibited good oral bioavailability in rats (Foral= 52%) [4]. The IC50 of AC 261066 to AKR1B10 is 51 ± 7μM. No inhibition of AC 261066 to AKR1B1 was detected when using up to 100 μM AC 261066 in the enzymatic assay [3].

Retinoic acid receptors (RARs, subtypes α, β, γ) form heterodimeric complexes with retinoid X receptors (RXR α, β, γ) to orchestrate complex events, such as organ homoeostasis, immune function, development and reproduction [1]. RARβ2 is an isoform of subtype β of retinoic acid receptor, its affinity to retinoids and biological functions are different from other isoforms [2].

AC 261066 did not induce the cell adhesion of RPMI 8866 B cells to the ADAM28 disintegrin-like domain and did not block the atRA-induced adhesion [5].

AC 261066-treatment significantly inhibited the tail regeneration process in N. viridescens compared to DMSO controls. When these AC 261066-treated newts were removed from AC 261066 at 21 days (time of analysis) and then placed back into normal pond water, tail regeneration commenced. Five weeks after removal from the AC 26l066, the tail had regenerated, albeit with an alteration in the dorsal-ventral patterning compared to a normal tail regenerate [6].

References:
[1].  Albane le Maire, Susana Alvarez, Pattabhiraman Shankaranarayanan, et al. Retinoid Receptors and Therapeutic Applications of RAR/RXR Modulators. Current Topics in Medicinal Chemistry, 2012, 12: 505-527.
[2].  Christopher R. Gardner, Belamy B. Cheung, Jessica Koach, et al. Synthesis of retinoid enhancers based on 2-aminobenzothiazoles for anti-cancer therapy. Bioorg. Med. Chem., 2012, 20: 6877-6884.
[3].  Sergio Porté, Joan Giménez, Marta Dominguez, et al. Aldo–keto reductases in retinoid metabolism: Search for substrate specificity and inhibitor selectivity. Chemico-Biological Interactions, 2013, 202(1-3):186-94.
[4].  Birgitte W. Lund, Fabrice Piu, Natalie K. Gauthier, et al. Discovery of a Potent, Orally Available, and Isoform-Selective Retinoic Acid β2 Receptor Agonist. J. Med. Chem., 2005, 48: 7517-7519.
[5].  Jarrett T. Whelan, Lei Wang, Jianming Chen, et al. Retinoids induce integrin-independent lymphocyte adhesion through RAR-α nuclear receptor activity. Biochemical and Biophysical Research Communications, 2014, 454: 537-542.
[6].  Christopher J. Carter. Identification of novel retinoid receptors and their roles in vertebrate and invertebrate nervous systems [D]. St. Catharines: Brock University, 2011.